Imperial College London
Portrait Picture

DrBenjaminSchumann

Faculty of Natural Sciences, Department of Chemistry

Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3796 5047b.schumann Website CV

 
 
//

Location

 

Francis Crick InstituteThe Francis Crick Institute

//

Summary

 

Publications

Citation

BibTex format

@article{Schumann:2018:10.1021/acscentsci.7b00504,
author = {Schumann, B and Reppe, K and Kaplonek, P and Wahlbrink, A and Anish, C and Witzenrath, M and Pereira, CL and Seeberger, PH},
doi = {10.1021/acscentsci.7b00504},
journal = {ACS Central Science},
pages = {357--361},
title = {Development of an efficacious, semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 1},
url = {http://dx.doi.org/10.1021/acscentsci.7b00504},
volume = {4},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Infections with Streptococcus pneumoniae are a major health burden. Glycoconjugate vaccines based on capsular polysaccharides (CPSs) successfully protect from infection, but not all pneumococcal serotypes are covered with equal potency. Marketed glycoconjugate vaccines induce low levels of functional antibodies against the highly invasive serotype 1 (ST1), presumably due to the obscuring of protective epitopes during chemical activation and conjugation to carrier proteins. Synthetic oligosaccharide antigens can be designed to carry linkers for site-selective protein conjugation while keeping protective epitopes intact. Here, we developed an efficacious semisynthetic ST1 glycoconjugate vaccine candidate. A panel of synthetic oligosaccharides served to reveal a critical role of the rare aminosugar, 2-acetamido-4-amino-2,4,6-trideoxy-d-galactose (d-AAT), for ST1 immune recognition. A monovalent ST1 trisaccharide carrying d-AAT at the nonreducing end induced a strong antibacterial immune response in rabbits and outperformed the ST1 component of the multivalent blockbuster vaccine Prevenar 13, paving the way for a more efficacious vaccine.
AU  - Schumann,B
AU  - Reppe,K
AU  - Kaplonek,P
AU  - Wahlbrink,A
AU  - Anish,C
AU  - Witzenrath,M
AU  - Pereira,CL
AU  - Seeberger,PH
DO  - 10.1021/acscentsci.7b00504
EP  - 361
PY  - 2018///
SN  - 2374-7943
SP  - 357
TI  - Development of an efficacious, semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 1
T2  - ACS Central Science
UR  - http://dx.doi.org/10.1021/acscentsci.7b00504
UR  - http://hdl.handle.net/10044/1/82455
VL  - 4
ER  -
Download